Results 191 to 200 of about 86,601 (293)

Immune non‐response despite effective antiretroviral therapy in people living with HIV: A review of potential mechanisms, biomarkers and therapeutic approaches

open access: yesHIV Medicine, EarlyView.
Abstract Introduction A proportion of people living with HIV (PLWH) fail to restore their CD4 count or their CD4/CD8 ratio despite effective antiretroviral therapy (ART). PLWH with immune non‐response (INR) are at a higher risk of both AIDS and non‐AIDS events. The underlying mechanisms of INR remain unclear.
Charlotte Silvestre   +2 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos   +6 more
wiley   +1 more source

A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. [PDF]

open access: yesClin Cancer Res
Strati P   +18 more
europepmc   +1 more source

Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure [PDF]

open access: bronze, 2019
Emily C. Ayers   +39 more
openalex   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska   +8 more
wiley   +1 more source

Data from First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non–Hodgkin Lymphoma

open access: gold
Jennifer A. Woyach   +15 more
openalex   +1 more source

Home - About - Disclaimer - Privacy